beta-lapachone has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, M | 1 |
| Ban, JJ | 1 |
| Chung, JY | 1 |
| Im, W | 1 |
| Kim, M | 1 |
1 other study available for beta-lapachone and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC-1α deacetylation.
Topics: Acetylation; Animals; Behavior, Animal; Cyclic AMP Response Element-Binding Protein; Gene Expression | 2018 |